Sanofi Himalya trial in ALS by Nazem Atassi and Merit Cudkowicz @EverythingALS
Sanofi Himalya trial in ALS by Nazem Atassi and Merit Cudkowicz  @EverythingALS
Uploaded December 2022 | Updated September 2026, 2 weeks ago
Dr. Merit (sue-code-vich) Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chief of Neurology at Mass General, Director and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. (sue-code-vich)’s Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS). She is one of the founders and past Co-Chairs of the Northeast ALS Consortium (NEALS), and is launching the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that will greatly accelerate therapy development in ALS.

Dr. Nazem(ah-toss-ee) Atassi is the Global Head of Early Neuro-Development at (sah-no-fee)Sanofi where he oversees the company’s early clinical development portfolio in neuroscience. He completed his Masters in Medical Sciences (MMSc) at Harvard Medical School, Neurology training at Boston Medical Center, Fellowship in neuromuscular disorders at Mass General Hospital (MGH), and Masters in Business Administration (MBA) at (MIT). He continues to attend clinic at Mass General Hospital where he cares for ALS patients and their families.
Sanofi Himalya trial in ALS by Nazem Atassi and Merit CudkowiczDigital Biomarker to #CuringALSExpanding Mechanisms and Therapeutic Targets for ALSALS Therapies and Treatment Updates: Updates on PrimeC by Mr.Alon Ben-NoonAssistive Technology for Communication: From Selection to CustomizationsRecent Genomic and Proteomic Advances in ALS/FTD with Dr. Bryan TraynorHi from Pathfinders Shawn and JoePalliative Care for ALS: What is it? How can it help? How to access it?To Kill a Motor Neuron: Model systems in the lab to understand ALS in the clinicALS Citizen led ResearchRespiratory Conditions in ALSStories and Innovation in ALS Episode #19:  Detoxification & Biochemical Resilience with Dr. Shade
Everything ALS |

Sanofi Himalya trial in ALS by Nazem Atassi and Merit Cudkowicz

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER